Blog

DEEP RESEARCH · SAM CHUN DANG PHARM/GLP-1

Sam Chun Dang Pharm's Oral Semaglutide: A High-Risk Bet That Could Change the Market

A biopharma memo on the GLP-1 market, S-PASS platform, patent strategy, and regulatory milestones

Written: 2025-07-23 · Pharmaceutical pipeline/patent-risk analysis · Original Naver Blog post

Investment decisions are your own responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

Sam Chun Dang's oral semaglutide has major scientific and commercial potential, but its final value will likely be decided by patent disputes, partnerships, manufacturing scale, and rival drug data. The source's core message is that this is not just a clinical-data story; it is also a courtroom and negotiation-table story.

1. Why the GLP-1 market matters

Official fact: The source explains that GLP-1 receptor agonists are changing diabetes and obesity treatment through glucose control, appetite suppression, and delayed gastric emptying.

GLP-1 mechanism mapOne hormone pathway acts on several metabolic control points
PancreasGlucose-dependent insulin secretion
BrainLower appetite and higher satiety
StomachDelayed gastric emptying
CardiovascularAdded event-reduction value
The challenge is that natural GLP-1 is rapidly degraded by DPP-4, requiring drug engineering.

Interpretation: Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound opened the injectable market. The next frontier is whether the therapy can be delivered as a pill.

2. Value and difficulty of oral formulations

  • Peptide drugs are vulnerable to stomach acid and digestive enzymes and are hard to absorb through the intestinal wall.
  • Novo Nordisk's Rybelsus is the leading oral semaglutide example, using the SNAC absorption enhancer.
  • If oral GLP-1 succeeds, it lowers injection aversion and improves convenience, broadening market access.

3. Sam Chun Dang's strategy: Rybelsus generic and S-PASS

TARGET

First global generic

The source frames the company's goal as launching the first generic version of Novo Nordisk's oral semaglutide, Rybelsus.

TECH

S-PASS

S-PASS is described as a proprietary platform intended to protect large molecules in the digestive tract and improve absorption.

RISK

Patent wall

The central question is whether the formulation can actually avoid Novo Nordisk's patent estate.

Official fact: The source notes that a 2020 WIPO international search report raised negative preliminary views on the original S-PASS-related PCT filing, while also noting that this was not a final judgment.

4. Clinical and regulatory milestones

Interpretation: A successful bioequivalence test would be an important scientific and regulatory signal, but it does not guarantee commercialization. FDA/EMA filings, definitive agreements, patent litigation, and CMO capacity still need to be confirmed.

Event to watchMeaningInvestor focus
FDA/EMA filingEntry into final regulatory stageNDA/MAA timing and deficiencies
Patent litigationPotential clash with Novo NordiskPreliminary injunction risk
Term sheet to final contractPartner validation of commercial valueUpfront payment and binding terms
Rival Phase 3 dataFuture efficacy benchmarkComparison with orforglipron and others
CMO/manufacturingAbility to meet global demandCost and supply reliability

5. Scenarios

Bull case

  • If launch happens in 2026, the patent dispute is won or settled favorably, and S-PASS cost competitiveness is proven, the company could capture meaningful share in a multi-billion-dollar oral GLP-1 market.
  • The source frames this as a transformative reward that could raise the company's scale and status to a global level.

Bear case

  • If Novo Nordisk's patent litigation succeeds and launch is delayed for years, the company may have to wait until the late 2030s.
  • By then, superior next-generation drugs and many low-cost generics may have erased the value of being first.

6. Final memo

Interpretation: This is not an investment case that ends with laboratory success. Patent war, bargaining power, manufacturing capacity, and rival clinical data may all determine the company's future value.

Sources

Naver original